Those with LDL-C > 80 mg/dl on stable statin therapy
Bococizumab versus placebo
54.2% versus 2.8%
Similar adverse events profile
Despite dose reduction in many subjects, bococizumab significantly reduced LDL-C across all the doses
(2)
SPIRE-1 and SPIRE-2
Those with background lipid-lowering treatment and have an LDL-C of 70 mg/dl (SPIRE-1) or LDL-C 100 mg/dl (SPIRE-2)
Bococizumab versus placebo
This study has been terminated. Completion date: Jan. 2017
Bococizumab being a humanized monoclonal antibody, a strong immune response was seen against it which mitigate the LDL-C lowering effect. Anti-drug Ab was seen in 48% patients and neutralizing Ab developed in 29% patients
